Biotech · Private company
Magenta Therapeutics, Inc.
Track this companyFree. Adds Magenta Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- MGTA-456Phase 2 · Inherited Metabolic Disorders (IMD)ClinicalTrials.gov · fetched Nov 12, 2026
- MGTA-117Phase 1 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Safety and efficacy assessmentsInherited Metabolic Disorders (IMD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)PHASE1 · TERMINATED · started Feb 14, 2022ClinicalTrials.gov NCT05223699 · fetched Nov 12, 2026
- A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456TERMINATED · started May 21, 2019ClinicalTrials.gov NCT04008849 · fetched Nov 12, 2026
- MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)PHASE2 · COMPLETED · started Feb 9, 2018ClinicalTrials.gov NCT03406962 · fetched Nov 12, 2026